Skip to main content
. 2021 Mar 16;51(2):43–64.

Table 1. Demographics and Baseline Characteristics—ITT Population.

Demographics and Baseline Characteristics Placebo SPN-812 Total
400-mg/day 600-mg/day
n 96 99 97 292
Age, years
 Mean (SD) 13.8 (1.53) 14.0 (1.74) 13.7 (1.52) 13.8 (1.60)
 Median (min, max) 14.0 (12, 17) 14.0 (12, 17) 13.0 (12, 17) 14.0 (12, 17)
Age group, n (%)
 12–14 years 63 (65.6) 61 (61.6) 72 (74.2) 196 (67.1)
 15–17 years 33 (34.4) 38 (38.4) 25 (25.8) 96 (32.9)
Gender, n (%)
 Male 61 (63.5) 66 (66.7) 71 (73.2) 198 (67.8)
 Female 35 (36.5) 33 (33.3) 26 (26.8) 94 (32.2)
Ethnicity, n (%)
 Not Hispanic and not Latino 63 (65.6) 65 (65.7) 66 (68.0) 194 (66.4)
 Hispanic or Latino 32 (33.3) 34 (34.3) 31 (32.0) 97 (33.2)
 Not allowed to ask as per local regulations 1 (1.0) 0 0 1 (0.3)
Race, n (%)
 White 64 (66.7) 63 (63.6) 66 (68.0) 193 (66.1)
 Black or African American 25 (26.0) 33 (33.3) 27 (27.8) 85 (29.1)
 Multiple 6 (6.3) 3 (3.0) 2 (2.1) 11 (3.8)
 American Indian or Alaska Native 1 (1.0) 0 1 (1.0) 2 (0.7)
 Native Hawaiian or other Pacific Islander 0 0 1 (1.0) 1 (0.3)
Weight (kg), mean (SD) 56.39 (12.897) 57.19 (11.883) 55.67 (13.253) 56.42 (12.657)
Body mass index
(kg/m2), mean (SD)
21.07 (3.582) 21.14 (3.512) 20.99 (3.310) 21.07 (3.458)
ADHD-RS-5, mean (SD)
 Total score 38.8 (8.06) 41.2 (7.80) 39.8 (8.34) 39.9 (8.10)
 Inattention 22.4 (3.59) 22.5 (3.70) 22.3 (3.82) 22.4 (3.69)
 Hyperactivity/Impulsivity 16.4 (6.36) 18.7 (5.59) 17.5 (6.49) 17.6 (6.21)
CGI-S, mean (SD) 4.5 (0.66) 4.8 (0.69) 4.6 (0.69) ND

ADHD-RS-5, ADHD Rating Scale-5; CGI-S, Clinical Global Impression-Severity of Illness; ITT, intent-to-treat; ND, not determined; SD, standard deviation.